Summary
Since 1985 the combination of chlorambucil (10 mg daily, initially for six weeks, then alternating fortnights for 12 weeks) and interferon-α2b (Schering-Plough; 2 × 106 U/m2 three times weekly by subcutaneous injection for 18 weeks) has been compared in a randomised trial with chlorambucil alone in previously untreated patients with stage III or IV follicular lymphoma. Responding patients have subsequently been randomised to receive maintenance interferon-α2b or no further treatment. Of the 124 treated patients, 108 are evaluable for response with a median follow-up of 30 months. The major toxicity was myelosuppression which was more frequent with chlorambucil and IFNα2b in combination than with chlorambucil alone (P < 0.01). There was no treatment-related mortality. Actuarial survival at three years is 75% for all patients, regardless of therapy. There was no significant difference in response rate according to initial therapy. For the 60 patients achieving a good response to initial therapy who have entered the second part of the trial, there has been a significant prolongation of remission duration in favour of maintenance IFN-α2b (median not yet reached versus two years for the ‘no treatment’ arm, P < 0.015). Fewest relapses have been seen in patients who received IFN-α2b throughout. Accrual to this trial continues; this preliminary analysis indicates that maintenance IFN-α2b may extend remission duration in follicular lymphoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Anderson T, DeVita VT, Simon SM et al. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708.
Lister TA, Cullen MH, Beard MEJ et al. Comparison of combined and single agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological type. Br Med J 1978; is 533.
Portlock CS, Rosenberg SA, Glatstein E, Kaplan HS. Treatment of advanced non-Hodgkin’s lymphomas with favourable histologies: Preliminary results of prospective trial. Blood 1976; 47 5: 747.
Glick JH, Barnes JM, Ezdinli EZ et al. Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920.
Peterson BA, Anderson JR, Frizzera G et al. Combination chemotherapy prolongs survival in follicular mixed lymphoma. Proc ASCO 1990; 9: 259.
Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470.
Foon KA, Sherwin SA, Abrams PG et al. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148.
Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. Am J Med 1986; 81: 871.
O’Connell MJ, Colgan JP, Oken MM et al. Clinical trial of recombinant leucocyte A interferon as initial therapy for favourable histology non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia: An ECOG pilot study. J Clin Oncol 1986; 4: 128–36.
Wagstaff J, Loynds P, Crowther D. A phase II study of human rDNA alpha-II interferon in patients with low grade non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 1986; 18: 54.
Chirigos MA, Pearson JW. Cure of murine leukaemia with drugs and interferon treatment. JNCI 1973; 14: 97.
Gresser I, Maury C, Tovey M. Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 1978; 14: 97.
Balkwill FR, Moodie EM. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1984; 44: 904.
Rohatiner AZS, Richards MA, Barnett MJ et al. Chlorambucil and interferon for low-grade non-Hodgkin’s lymphoma. Brit J Can 1987; 55: 437.
Quesada JR, Reuben JR, Manning JT et al. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15.
Talpaz M, Kantarjian HM, McCredie K. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N EnglJMed 1986; 314: 1065.
Kaplan EL, Meier R Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Spiegel RI. The alpha interferons: Clinical overview. Seminars in Oncology 1987; 14: (2) suppl. 2 1–12.
Akard LP, Hoffman R, Elias L, Saiers J. Alpha-interferon and Immune Haemolytic Anaemia. Ann Int Med 1986; 105: 306.
Braathen LR, Stavem R Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient: with mycosis fungoides. Brit Med J 1989; 298: 1713.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Price, C.G.A. et al. (1991). Interferon-α2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress. In: Ultmann, J.E., Samuels, B.L. (eds) Annals of Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7305-4_22
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7305-4_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7294-1
Online ISBN: 978-1-4899-7305-4
eBook Packages: Springer Book Archive